CoastWatcher
Moderator
It's known that inflammation is associated with (among other things) metabolic syndrome and obesity. Preliminary evidence suggested that resveratrol - popular/widely used as a dietary supplement - had both anti-inflammatory and positive metabolic effects and there was hope such effects could be demonstrated in a clinical/therapeutic setting.
Results
Journal of Clinical Endocrinology & Metabolism, 2017 May 1.
https://www.ncbi.nlm.nih.gov/m/pubmed/28182820/
- A randomized, placebo-controlled, double-blind study was undertaken with the enrollment of middle-aged, community-dwelling men with metabolic syndrome into one of three groups. Average age was 49.5 years, body mass index was 33.8, and waist circumference was 115 cm.
- Daily oral supplementation with 1000mg of resveratrol/150mg of resveratrol/placebo for 16 weeks.
- Patient blood draws measured high-sensitivity C-reactive protein (hs-CRP), circulating lipids, inflammatory markers were sought and evaluated in circulation and adipose/muscle tissue biopsy specimens, while glucose metabolism and visceral fat deposition were evaluated as well.
Results
- Resveratrol did not lower circulating levels of: hs-CRP, interleukin 6, or soluble urokinase plasminogen activator receptor in plasma. Inflammatory gene expression remained unchanged in adipose and muscle tissue.
- Resveratrol had no beneficial effect on blood pressure, body composition, lipid deposition in the liver or striated muscle.
- Resveratrol had no beneficial effect on lipid metabolism
- Resveratrol increased total cholesterol, LDL cholesterol, and fructosamine.
Journal of Clinical Endocrinology & Metabolism, 2017 May 1.
https://www.ncbi.nlm.nih.gov/m/pubmed/28182820/